The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Open accessAbstract
A common clinical conundrum faces all U.S. practitioners treating patients with type 2 diabetes. Today’s U.S. Food and Drug Administration prescribing guidelines for metformin contraindicate its use in men and women with serum creatinine concentrations ≥1.5 and ≥1.4 mg/dL (≥132 and ≥123 µmol/L), respectively. In a patient tolerating and controlled with this medication, should it automatically be discontinued as the creatinine rises beyond these cut points over time? Stopping metformin often results in poorly controlled glycemia and/or the need for other agents with their own adverse-effect profiles. Moreover, is the now widespread use of estimated glomerular filtration rate (eGFR) in lieu of serum creatinine levels creating even more confusion, especially in those with abnormalities in one but not the other indirect measure of renal function? Indeed, more than a decade and a half after metformin became available in the U.S., debate continues over the best approach in these settings (1–3). How many patients are unable to receive this medication on the basis of guidelines which, although well intentioned, are somewhat arbitrary and outdated based on modern assessments of renal status? There is some evidence that early treatment with metformin is associated with reduced cardiovascular morbidity and total mortality in newly diagnosed type 2 diabetic patients (4). However, the data come from a small subgroup of a much larger trial. In contrast, despite multiple trials of intensive glucose control using a variety of glucose-lowering strategies, there is a paucity of data to support specific advantages with other agents on cardiovascular outcomes (5–7). In the original UK Prospective Diabetes Study (UKPDS), 342 overweight patients with newly diagnosed diabetes were randomly assigned to metformin therapy (8). After a median period of 10 years, this subgroup experienced a 39% ( P = 0.010) risk reduction for myocardial infarction and a …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the occurrence of this complication is very rare (100) and primarily occurs when the estimated glomerular filtration rate (eGFR) is <30 mL/ min/1.73 m 2 (101).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [101]
Experimental — accuracy not yet measuredIn the citing paper
“Despite early concerns, the evidence for an increase in the risk of lactic acidosis with metformin is minimal.”
From Diabetes in Older Adults: A Consensus Report (2012) · cites this paper as [94]
In the citing paper
“These changes may translate into increased risk for hypoglycemia, potential need for reduced doses of certain medications, and attention to renal function to minimize side effects94, 95.”
From Diabetes in Older Adults: A Consensus Report (2012) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Self-citation
Flagged first, then by citations
1 of the 58 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- National Institute for Health and Clinical Excellence, 2010, The Management of Type 2 Diabetes: 2010 NICE Guidelines [Internet]
- U.S. Food and Drug Administration, 2008, Guidance for Industry Diabetes Mellitus: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Cited by
Sorted by citations
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationManagement of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Self-citationInker, L. A., Astor, B. C., Fox, C. H., Isakova, T., Lash, J. P., Peralta, C. A., Tamura, M. K., & Feldman, H. I. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.01.416 · Cited by 1,828
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Kirkman, M. S., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., Huang, E. S., Korytkowski, M. T., Munshi, M. N., Odegard, P. S., et al. (2012) · Diabetes Care · doi:10.2337/dc12-1801 · Cited by 1,274
Diabetic kidney disease: a report from an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1296 · Cited by 1,153
Diabetic Kidney Disease: A Report From an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein‐Fuchs, J., Hirsch, I. B., Kalantar‐Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.08.001 · Cited by 905
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., DeFronzo, R. A., EINHORN, D. F., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 879
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M. A., Peters, A. L., Τσάπας, Α., Wender, R. C., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 701
Self-citationUpdate on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Metformin-associated lactic acidosis: current perspectives on causes and risk
DeFronzo, R., Fleming, G. A., Chen, K., & Bicsak, T. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.10.014 · Cited by 658
Metformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review
Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J., & McGuire, D. K. (2014) · JAMA · doi:10.1001/jama.2014.15298 · Cited by 601
Self-citationGarber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
Diabetes in Older Adults: A Consensus Report
Sue Kirkman, M., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., Huang, E. S., Korytkowski, M. T., Munshi, M. N., Odegard, P. S., et al. (2012) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12035 · Cited by 548
Bozkurt, B., Aguilar, D. A., Deswal, A. M., Dunbar, S. B., Francis, G. S., Horwich, T. B., Jessup, M. L., Kosiborod, M., Pritchett, A. M., Ramasubbu, K., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000450 · Cited by 556
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., DeFronzo, R. A., EINHORN, D. F., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 503
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
Type-2 diabetes mellitus and cardiovascular disease
Henning, R. J. (2018) · Future Cardiology · doi:10.2217/fca-2018-0045 · Cited by 398
Vassalotti, J. A., Centor, R., Turner, B. J., Greer, R. C., Choi, M., & Sequist, T. D. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.08.025 · Cited by 291
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M. A., Peters, A. L., Τσάπας, Α., Wender, R. C., & Matthews, D. R. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.3.154 · Cited by 291
Self-citationStorozhuk, Y., Hopmans, S., Sanli, T., Barron, C. C., Tsiani, E., Cutz, J.-C., Pond, G. R., Wright, J. R., Singh, G., & Tsakiridis, T. K. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.187 · Cited by 276
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
Molitch, M. E., Adler, A. I., Flyvbjerg, A., Nelson, R. G., So, W.-Y., Wanner, C., Kasiske, B. L., Wheeler, D. C., de Zeeuw, D., & Mogensen, C. E. (2015) · Kidney International · doi:10.1038/ki.2014.128 · Cited by 268
Peri‐operative management of the surgical patient with diabetes 2015
Party, M. O. T. W., Barker, P., Creasey, P. E., Dhatariya, K., Levy, N., Lipp, A., Nathanson, M. H., Penfold, N. W., Watson, B., & Woodcock, T. (2015) · Anaesthesia · doi:10.1111/anae.13233 · Cited by 265
Drawz, P. E., & Rahman, M. U. (2015) · Annals of Internal Medicine · doi:10.7326/aitc201506020 · Cited by 242
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.csuppl · Cited by 219
Wu, B., Bell, K. F., Stanford, A. H., Kern, D. M., Tunceli, O., Vupputuri, S. X., Kalsekar, I. D., & Willey, V. J. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000154 · Cited by 223
Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy
Longo, M., Bellastella, G., Maiorino, M. I., Meier, J. J., Esposito, K., & Giugliano, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00045 · Cited by 204
Anti-senescence compounds: A potential nutraceutical approach to healthy aging
Gurău, F., Baldoni, S., Prattichizzo, F., Espinosa, E., Amenta, F., Procopio, A. D., Albertini, M. C., Bonafè, M., & Olivieri, F. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.05.001 · Cited by 179
Scheen, A. J., & Paquot, N. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.02.006 · Cited by 174
Interactions between kidney disease and diabetes: dangerous liaisons
Pecoits‐Filho, R., Abensur, H., Betônico, C. D. C. R., Machado, A. D., Parente, E. B., Queiroz, M. S., Salles, J. E. N., Titan, S., & Vencio, S. A. C. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0159-z · Cited by 180
Eppenga, W. L., Lalmohamed, A., Geerts, A. F. J., Derijks, H. J., Wensing, M., Egberts, T. C. G., Smet, P. A. G. M. D., & de Vries, F. (2014) · Diabetes Care · doi:10.2337/dc13-3023 · Cited by 168
Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function
Lazarus, B., Wu, A., Shin, J., Sang, Y., Alexander, G. C., Secora, A. M., Inker, L. A., Coresh, J., Chang, A. R., & Grams, M. E. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0292 · Cited by 171
Udell, J. A., Bhatt, D. L., Braunwald, E., Cavender, M. A., Mosenzon, O., Steg, P. G., Davidson, J. A., Nicolau, J. C., Corbalan, R. L., Hirshberg, B., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1850 · Cited by 163
Updates on the Management of Diabetes in Dialysis Patients
Rhee, C. M., Leung, A. M., Kovesdy, C. P., Lynch, K. E., Brent, G. A., & Kalantar‐Zadeh, K. (2014) · Seminars in Dialysis · doi:10.1111/sdi.12198 · Cited by 158
Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.07.017 · Cited by 156
Review of Biguanide (Metformin) Toxicity
Wang, G. S., & Hoyte, C. O. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618793385 · Cited by 164
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 173
Natural Nrf2 activators in diabetes
Jiménez‐Osorio, A. S., González-Reyes, S., & Pedraza‐Chaverrí, J. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.07.009 · Cited by 148
Nephroprotective Effects of Metformin in Diabetic Nephropathy
Ravindran, S., Kuruvilla, V. M., Wilbur, K., & Munusamy, S. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25598 · Cited by 135
Diabetes Management in the Elderly
Leung, E., Wongrakpanich, S., & Munshi, M. N. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0033 · Cited by 131
9. Microvascular Complications and Foot Care
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s012 · Cited by 136
Review of Hypoglycemia in the Older Adult: Clinical Implications and Management
Sircar, M., Bhatia, A., & Munshi, M. N. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.10.004 · Cited by 136
the Italian Diabetes Society and the Italian Society of Nephrology, Pugliese, G., Penno, G., Natali, A., Barutta, F., Paolo, S. D., Reboldi, G., Gesualdo, L., & Nicola, L. D. (2019) · Journal of Nephrology · doi:10.1007/s40620-019-00650-x · Cited by 135
Hypoglycemia in Patients with Diabetes and Renal Disease
Alsahli, M., & Gerich, J. E. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4050948 · Cited by 127
Medication Safety Principles and Practice in CKD
Whittaker, C. F., Miklich, M. A., Patel, R. S., & Fink, J. C. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00580118 · Cited by 129
9. Microvascular Complications and Foot Care
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s012 · Cited by 124
Richy, F. F., Sabidó, M., Guedes, S., Corvino, F. A., & Gottwald‐Hostalek, U. (2014) · Diabetes Care · doi:10.2337/dc14-0464 · Cited by 124
Personalized Diabetes Management Using Electronic Medical Records
Bertsimas, D., Kallus, N., Weinstein, A., & Zhuo, Y. D. (2016) · Diabetes Care · doi:10.2337/dc16-0826 · Cited by 122
Metformin: Therapeutic profile in the treatment of type 2 diabetes
Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 143
Self-citationMechanism and application of metformin in kidney diseases: An update
Song, A., Zhang, C., & Meng, X. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111454 · Cited by 121
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
Wilcox, T., Block, C. E. M. D., Schwartzbard, A. Z., & Newman, J. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.056 · Cited by 124
Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride
Çetin, M., & Şahin, S. (2015) · Drug Delivery · doi:10.3109/10717544.2015.1089957 · Cited by 111
A review of phenformin, metformin, and imeglimin
Yendapally, R., Sikazwe, D., Kim, S. S., Ramsinghani, S., Fraser‐Spears, R., Witte, A. P., & Viola, B. L. (2020) · Drug Development Research · doi:10.1002/ddr.21636 · Cited by 111
Scheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0198-2 · Cited by 102
Triggle, C. R., & Ding, H. (2015) · Acta Physiologica · doi:10.1111/apha.12644 · Cited by 101
Pharmacologic Treatment of Type 2 Diabetes
Tran, L., Zielinski, A., Roach, A. H., Jende, J. A., Householder, A. M., Cole, E. E., Atway, S. A., Amornyard, M., Accursi, M. L., Shieh, S. W., et al. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014558289 · Cited by 102
Tratamiento de la diabetes tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Díez‐Espino, J., Formiga, F., Tejedor, J. L., Rodríguez‐Mañas, L., González-Sarmiento, E., Torre, E. L. M., & Sangrós, J. (2012) · Medicina Clínica · doi:10.1016/j.medcli.2012.10.003 · Cited by 96
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
Scheen, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.777428 · Cited by 91
Schlender, L., Martinez, Y. V., Adeniji, C., Reeves, D., Faller, B., Sommerauer, C., Qur‵an, T. A., Woodham, A., Kunnamo, I., Sönnichsen, A. C., et al. (2017) · BMC Geriatrics · doi:10.1186/s12877-017-0574-5 · Cited by 91
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 99
Arnouts, P., Bolignano, D., Nistor, I., Bilo, H. J. G., Gnudi, L., Heaf, J. G., & Biesen, W. V. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft462 · Cited by 89
Wissing, K. M., & Pipeleers, L. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2013.12.004 · Cited by 83
Management of Diabetes in the Elderly
Bansal, N., Dhaliwal, R., & Weinstock, R. S. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.11.008 · Cited by 82
Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy
Johnson, S. A., & Spurney, R. F. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2015 · Cited by 76
Diabetes treatment in patients with renal disease: Is the landscape clear enough?
Ioannidis, I. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.651 · Cited by 74
Hsu, W., Hsiao, P., Lin, P.-C., Chen, S., Lee, M., & Shin, S. (2017) · Oncotarget · doi:10.18632/oncotarget.23387 · Cited by 75
Morgan, C. L., Mukherjee, J., Jenkins‐Jones, S., Holden, S. E., & Currie, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12302 · Cited by 72
The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes
Amod, A. (2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872276 · Cited by 69
Use of Renally Inappropriate Medications in Older Veterans: A National Study
Chang, F., O’Hare, A. M., Miao, Y., & Steinman, M. A. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13790 · Cited by 69
Treatment Approach to Patients With Severe Insulin Resistance
Church, T., & Haines, S. T. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.2.97 · Cited by 75
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Self-citation(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.67 · Cited by 62
Jia, Y., Lao, Y., Zhu, H., Li, N., & Leung, S.-W. (2018) · Obesity Reviews · doi:10.1111/obr.12753 · Cited by 65
Metformin as a Potential Agent in the Treatment of Multiple Sclerosis
Dziedzic, A., Saluk, J., Miller, E. D., & Bijak, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175957 · Cited by 62
Metformin Use in Kidney Transplant Recipients in the United States: An Observational Study
Stephen, J., Anderson-Haag, T. L., Gustafson, S. K., Snyder, J. J., Kasiske, B. L., & Israni, A. K. (2014) · American Journal of Nephrology · doi:10.1159/000370034 · Cited by 61
The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised)
(2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872287 · Cited by 58
Metformin associated lactic acidosis (MALA): clinical profiling and management
Moioli, A., Maresca, B., Manzione, A., Napoletano, A., Coclite, D., Pirozzi, N., Punzo, G., & Mené, P. (2016) · Journal of Nephrology · doi:10.1007/s40620-016-0267-8 · Cited by 60
Optimal therapy of type 2 diabetes: a controversial challenge
Dardano, A., Penno, G., Prato, S. D., & Miccoli, R. (2014) · Aging · doi:10.18632/aging.100646 · Cited by 58
Lactic acidosis: relationship between metformin levels, lactate concentration and mortality
Boucaud‐Maitre, D., Ropers, J., Porokhov, B., Altman, J., Bouhanick, B., Doucet, J., Girardin, E., Kaloustian, E., Vague, V. L., & Emmerich, J. (2016) · Diabetic Medicine · doi:10.1111/dme.13098 · Cited by 58
Boerner, B. P., Miles, C. D., & Shivaswamy, V. (2014) · International Journal of Endocrinology · doi:10.1155/2014/617638 · Cited by 55
Mary, A., Hartemann, A., Liabeuf, S., Aubert, C. E., Kemel, S., Salem, J., Cluzel, P., Lenglet, A., Massy, Z. A., Lalau, J., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0509-7 · Cited by 56
Erler, A., Beyer, M., Petersen, J. J., Saal, K., Rath, T., Rochon, J., Haefeli, W. E., & Gerlach, F. M. (2012) · BMC Family Practice · doi:10.1186/1471-2296-13-91 · Cited by 55
The importance of synthetic drugs for type 2 diabetes drug discovery
Safavi, M., Foroumadi, A., & Abdollahi, M. R. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.837883 · Cited by 52
Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2017.12.003 · Cited by 57
Metformin-Associated Lactic Acidosis
Pasquel, F. J., Hinedi, Z., Umpierrez, G. E., Klein, R., Adigweme, A., Coralli, R. J., Pimentel, J., & Lopez, F. A. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3182a562b7 · Cited by 53
Groop, P., Prato, S. D., Taskinen, M., Owens, D. R., Gong, Y., Crowe, S., Patel, S., von Eynatten, M., & Woerle, H. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12281 · Cited by 51
Kajbaf, F., Arnouts, P., Broe, M. E. D., & Lalau, J. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3501 · Cited by 50
Effects of metformin on blood and urine pro-inflammatory mediators in patients with type 2 diabetes
Chen, W., Liu, X., & Ye, S. (2016) · Journal of Inflammation · doi:10.1186/s12950-016-0142-3 · Cited by 50
Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?
Giaccari, A., Solini, A., Frontoni, S., & Prato, S. D. (2021) · Diabetes Care · doi:10.2337/dc20-1964 · Cited by 54
Treatment of type 2 diabetes mellitus in elderly patients
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.12.004 · Cited by 48
Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study
Christiansen, C. F., Johansen, M. B., Christensen, S., O’Brien, J. M., Tønnesen, E., & Sørensen, H. T. (2013) · Critical Care · doi:10.1186/cc12886 · Cited by 48
Dutta, D., & Mukhopadhyay, S. (2016) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.184281 · Cited by 48
[Consensus document on treatment of type 2 diabetes in patients with chronic kidney disease].
Gómez‐Huelgas, R., Martínez‐Castelao, A., Artola, S., Górriz, J. L., & Menéndez, E. (2014) · PubMed · Cited by 47
Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients
Mendez, C. E., & Umpierrez, G. E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.3.180 · Cited by 48
Metadata
- Authors
- Lipska, K. J., Bailey, C. J., & Inzucchi, S. E.
- Affiliations
- Yale University (US)
- Aston University (GB)
- Corresponding author
- Inzucchi, Silvio E.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-05-20
- Volume
- 34
- Issue
- 6
- Pages
- 1431-1437
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3114336
- OpenAlex
- W2154719797
- Cited by
- 432
- References
- 58
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 15 · 2023: 8 · 2022: 11 · 2021: 17 · 2020: 17 · 2019: 26 · 2018: 34 · 2017: 28 · 2016: 45 · 2015: 50 · 2014: 65 · 2013: 42 · 2012: 42
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Aston Publications Explorer (Aston University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- metformin, renal failure, type 2 diabetes, serum creatinine, estimated glomerular filtration rate, metformin discontinuation, cardiovascular outcomes, glycemic control, UK Prospective Diabetes Study
- MeSH terms
- Contraindications, Acidosis, Lactic, Creatinine, Diabetes Mellitus, Type 2, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Myocardial Infarction, Practice Guidelines as Topic, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
